Using Virtual Reality to Improve Antiretroviral Therapy Adherence in the Treatment of HIV: Open-Label Repeated Measure Study

Abstract

Background Nonadherence to HIV medications is a serious unsolved problem and is a major cause of morbidity and mortality in the HIV-positive population. Although treatment efficacy is high if compliance is greater than 90%, about 40% of people with HIV do not meet this threshold. Objective This study aimed to test a novel approach to improve medication adherence by using a low-cost virtual reality (VR) experience to educate people with HIV about their illness. We hypothesized that people with HIV would be more likely to be compliant with the treatment following the 7-minute experience and, therefore, should have decreasing viral load (VL), increasing cluster of differentiation 4 + (CD4 + ) cell counts, and improved self-reported adherence. Methods We showed the VR experience to 107 participants with HIV at a county hospital in Los Angeles, California. Participants were asked to self-report how often they take their medications on a Likert-scale. The self-reported question (SRQ) was given before and at least 2 weeks after the VR experience. We also compared VL and CD4 + cell counts before and on average 101 days after the experience. VL and CD4 + were obtained per the clinic’s standard care protocol. Two-tailed paired t tests were performed on the initial and follow-up SRQ scores, VL, and CD4 + . We restricted the CD4 + analysis to participants who had a pre-CD4 + below normal (defined as 500 cells/mm 3 ). To reduce the possibility that VL were trending down and CD4 + were trending up regardless of the VR experience, 2 serial VL and CD4 + obtained before the experience were also compared and analyzed. Immediately following the VR experience, participants were given a 4-question Likert-type postexperience questionnaire (PEQ) that assessed their opinions about the experience. Results SRQ scores improved from pre to post experience with high significance ( P <.001). VL decreased from pre to post experience by 0.38 log 10 copies/mL (95% CI 0.06-0.70; P =.02). In contrast, the 2 serial VL obtained before the experience showed no statistically significant changes. There was also a statistically significant increase in CD4 + (95% CI –3.4 to –54.3 cells/mm 3 ; P =.03). Analysis of the PEQ revealed that VR was comfortable for almost all of the participants and that most participants believed the experience to be educational and that it would improve their medication adherence. Conclusions The findings suggest that the low-cost VR experience c...

Technology-Delivered Intervention Strategies to Bolster HIV Testing

“…Study findings showed participant experience resulted in decreased viral load and increased CD4(+). Participants stated the experience was comfortable, educational, and that it would help increase adherence [ 75 ]. VR scenarios can be developed to help increase self-efficacy in discussing STI testing with sexual partners or with a healthcare provider.…”

Effectiveness of instant versus text messaging intervention on antiretroviral therapy adherence among men who have sex with men living with HIV

“… 35 Incorporating interactive elements like gamification and virtual reality technology into IMI can enhance user experiences, facilitate social connections, and improve adherence. 36 …”

Developing an app-based self-management program for people living with HIV: a randomized controlled pilot study during the COVID-19 pandemic

“…The factors influencing the usability of apps include both usefulness of its information, and its easy manipulation, playfulness 43 , and trustworthiness 44 . The app developed in this study did not include elements that could build trust with the users, elements that could increase interest such as through virtual reality 45 or gamified team-building 46 , and the user experience design process. In addition, another study on self-management app usability among PLWH found that the usability of the app sections differed according to the participants' HIV infection stage 47 .…”